Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 53

Results For "NDA"

4736 News Found

Surya Brasil eyes India expansion after 30% US growth
News | February 23, 2026

Surya Brasil eyes India expansion after 30% US growth

The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner


Bavarian Nordic bags $22.5M Canadian vaccine order
News | February 23, 2026

Bavarian Nordic bags $22.5M Canadian vaccine order

The order will cover the manufacturing of bulk vaccine in 2026


VivaMed BioPharma teams up with Syngene International to fast-track AI-driven drug programmes
News | February 23, 2026

VivaMed BioPharma teams up with Syngene International to fast-track AI-driven drug programmes

The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities


Morepen Labs lands record Rs. 825 crore global CDMO contract
News | February 23, 2026

Morepen Labs lands record Rs. 825 crore global CDMO contract

This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major


Maverick Simulation Solutions unveils ‘SIDDH’, India’s next-gen critical care patient simulator
Healthcare | February 22, 2026

Maverick Simulation Solutions unveils ‘SIDDH’, India’s next-gen critical care patient simulator

Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them


Lilly’s Retevmo shows breakthrough results in early-stage lung cancer trial
Clinical Trials | February 22, 2026

Lilly’s Retevmo shows breakthrough results in early-stage lung cancer trial

The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns


FDA accepts Roche’s new drug application for Giredestrant in advanced breast cancer
Drug Approval | February 21, 2026

FDA accepts Roche’s new drug application for Giredestrant in advanced breast cancer

The NDA filing is supported by results from the phase III evERA Breast Cancer study


FDA greenlights first all-oral, fixed-duration combo therapy for untreated CLL patients
Drug Approval | February 21, 2026

FDA greenlights first all-oral, fixed-duration combo therapy for untreated CLL patients

The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy


Novartis bags Phase III win for Remibrutinib in chronic inducible urticaria
Clinical Trials | February 20, 2026

Novartis bags Phase III win for Remibrutinib in chronic inducible urticaria

The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options